Atea Pharmaceuticals Earnings Preview
Portfolio Pulse from Benzinga Insights
Atea Pharmaceuticals (NASDAQ:AVIR) is scheduled to release its quarterly earnings report on February 28, 2024, with an estimated EPS of $-0.50. Investors are hopeful for a beat on this estimate and positive guidance for future growth. Despite beating EPS estimates in the past, Atea Pharmaceuticals has experienced mixed stock price reactions post-earnings. The stock is currently trading at $4.32, reflecting a 39.54% increase over the last 52 weeks.
February 27, 2024 | 8:02 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Atea Pharmaceuticals is expected to announce its quarterly earnings with an anticipated EPS of $-0.50. The company's past earnings have shown a tendency to beat estimates but with mixed stock price reactions. Currently, the stock has seen a significant year-over-year increase.
Given Atea Pharmaceuticals' history of beating EPS estimates but experiencing mixed reactions in stock price, the short-term impact is uncertain. The anticipation of positive guidance could provide upward momentum, but past performance suggests investor reactions can vary. The 39.54% YOY stock increase indicates a positive long-term sentiment, yet the immediate reaction to the earnings report remains unpredictable.
CONFIDENCE 80
IMPORTANCE 90
RELEVANCE 100